Your browser doesn't support javascript.
loading
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas, Tony; Pfister, Thomas D; Colantonio, Simona; Aziz, Amina; Dieckman, Lynda; Saul, Richard G; Kaczmarczyk, Jan; Borgel, Suzanne; Alcoser, Sergio Y; Hollingshead, Melinda G; Lee, Young H; Bottaro, Donald P; Hiltke, Tara; Whiteley, Gordon; Takebe, Naoko; Kinders, Robert J; Parchment, Ralph E; Tomaszewski, Joseph E; Doroshow, James H.
Afiliación
  • Navas T; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Pfister TD; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Colantonio S; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Aziz A; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America.
  • Dieckman L; Biosciences Division, Argonne National Laboratory, Argonne, Illinois, United States of America.
  • Saul RG; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Kaczmarczyk J; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Borgel S; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
  • Alcoser SY; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
  • Hollingshead MG; Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
  • Lee YH; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Bottaro DP; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Hiltke T; Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Whiteley G; Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Kinders RJ; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Parchment RE; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
  • Tomaszewski JE; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
PLoS One ; 13(6): e0199361, 2018.
Article en En | MEDLINE | ID: mdl-29928062
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Transición Epitelial-Mesenquimal / Microambiente Tumoral / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Transición Epitelial-Mesenquimal / Microambiente Tumoral / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos